To register: https://bit.ly/305jpF8 The 3rd and final webinar in the current LAB150-TIAP series will be held on Tuesday, March 23. Please see the link above to register. There are limited number of openings, so please register soon. Feel free to circulate to senior scientists in your…
Tag: drug development
Webinar February 24, 2021 – Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule
On February 24, LAB150 together with TIAP hosts a webinar entitled Adventures in Drug Hunting: Identify and Advance Your Drug-Like Molecule. Please see the link below for more information and to register. There are limited number of openings, so please register soon. Feel free to circulate to senior…
Webinar: Staying on Target: Is your research program ready for drug discovery?
Staying on Target: How to Determine if Your Research Program is Ready for Drug Discovery LAB150 Presents: A 3-part Webinar Series on Drug Discovery and Development Register here: bit.ly/Stay-On-Target In the first of three webinars in the LAB150 series on drug discovery and development, we…
Project 7: Novel Therapeutic Agent for Immuno-Oncology from Sunnybrook Research Institute
Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his…
Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in…
Mental Health is the Focus of Our Fifth Project
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) — It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take…
Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) — MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both…
First Project Announced!
Hamburg, Germany, and Toronto, Canada, Feb. 15, 2018 (GLOBE NEWSWIRE) — Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership. After signing a collaboration agreement in…